Hovione Macau

Manufacturing Plant

Established in 1986, the site was first approved by the FDA in 1987 and is regularly inspected.

Manufacturing Plant in Macau, China | Hovione

Hovione Macau was established in 1986 and has since been upgraded to boost production capacity as well as to install waste water treatment facilities. The plant was first approved by the FDA in 1987 and is regularly inspected. The plant holds a GMP Certificate issued by Infarmed, the Portuguese Health Authority.

With a total reactor capacity of approximately 100m3, Hovione Macau produces both generic and custom synthesis products. The plant benefits from its proximity to the People’s Republic of China for the supply of raw materials.

Area of Focused Expertise

The site has leading capabilities and physical assets in the following areas:

  • Cryogenic (Volume 6000L, Temperature Range -65 to 140ºC)
  • Hydrogenation (Volume 600L to 6000L, Pressure Rating 10 to 20bar)
  • Tetracycline and Macrolide chemistry

For details about production equipment – click here

Operations

  • The Macau plant operates 24 hours a day 7 days a week.
  • Quality Control labs supports production 24 hours a day 7 days a week.
  • Plant maintenance shutdown period takes place for 3 to 4 weeks in August.

Certifications

The site is certified in accordance with the ISO9001; ISO14001 and OHSAS18001.

 

 
 

For inquiries about Hovione Macau, kindly fill the form below.

News

CDMO Hovione and biotechnology company Firstgene Life Sciences (of Xlife Sciences) have collaborated to advance Hovione’s drug delivery platform for the targeted treatment of Hepatocellular Carcinoma (HCC). “We are proud to advance the development of innovative oncology treatments that address a critical unmet need for precision gene expression at the tissue level,” said Hovione CEO Dr Jean-Luc Herbeaux. The virus-like particle technology will be engineered and functionalised for the specific carcinoma cell type using therapeutically validated AAVs, including a novel primer compound. Hovione will be responsible for molecular engineering, the supply of tailor-made virus-like particles and the execution of proof-of-concept studies. “HCC, the most common liver cancer and a leading cause of cancer-related death, continues to represent a major unmet medical need,” said Firstgene managing director Dr Alexander Zink. “The combination of Hovione’s expertise in complex chemistry and particle engineering and the commercialisation expertise of Xlife Sciences positions Firstgene well to offer patients potential new safe and effective therapy options.”   Read the full article at scientistlive.com    

Press Clipping
Scientist Live, 12 May 2025

Partnership advances liver cancer treatment

May 12, 2025
Manufacturing Plant
Address

Hovione PharmaScience Ltd
Estrada Coronel Nicolau de Mesquita
Taipa
Macau
Tel: +853 2882 7544
Fax: +853 2882 7714
e-mail: infohm@hovione.com
DUNS Nr: 854974342 
Location: 22°09'28.62" N  113°33'40.58" E

FDA logo | Hovione
infarmed logo | Hovione
Hovione MACAU - ISO14001 and ISO45001
HKQAA Certified Company | Hovione

Other Locations

Hovione Hong Kong

Office
Address

Hovione Holding Asia Limited
Aubin House, 11th Floor
171-172 Gloucester Road
Wanchai
Hong Kong SAR
Tel.: +852 2891 1836
Fax: +852 2891 0943 

View all details

Hovione India

Office
Address

Hovione Holding Limited
C/o WeWork, 2nd floor,
Oberoi Commerz - II,  1,
Off Western Express Highway,
Oberoi Garden City, Goregaon East, Mumbai, Maharashtra 400063
India
Tel.: +919 004 261 523

View all details